RYTM250117C20000
- 0.00
- 0.000.00%
Rhythm Pharmaceuticals Newsroom
Rhythm Pharmaceuticals Price Target Maintained With a $69.00/Share by HC Wainwright & Co.
JMP Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $75
JMP Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $75
Strategic Advancements and Market Potential Drive Buy Rating for Rhythm Pharmaceuticals
Oppenheimer Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $76
Rhythm Pharmaceuticals Initiated at Outperform by Oppenheimer
Rhythm Pharmaceuticals Price Target Announced at $76.00/Share by Oppenheimer
Goldman Sachs Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $66
Rhythm Pharmaceuticals Price Target Raised to $66.00/Share From $59.00 by Goldman Sachs
Rhythm Pharmaceuticals Is Maintained at Buy by Goldman Sachs
JMP Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $75
H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $69
Rhythm Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $69
Stifel Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $78
TD Cowen Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $65
Rhythm Pharmaceuticals Analyst Ratings
A Quick Look at Today's Ratings for Rhythm Pharmaceuticals(RYTM.US), With a Forecast Between $58 to $80
TD Cowen Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals' Advancements in Setmelanotide Trials Signal Strong Buy Rating